Tumour ablation market projected to grow at 10% CAGR until 2029

The liver cancer segment is expected to witness notable growth within the forecast period.

The global tumour ablation market is estimated to reach $1.4b in terms of revenue at a compound annual growth rate (CAGR) of 10% until 2029, according to MarketsandMarkets.

The report revealed that advancements in technology, new product developments in cryoablation, and the growing incidence of cancer are the major indicators contributing to the market’s expansion.

By application, the liver cancer segment is poised to witness notable growth until 2029 supported by a consistent rise in global hepatocellular carcinoma cases, clinical studies showing improved success rate, and the increasing proportion of the older age population.

Meanwhile, the Asia-Pacific (APAC) market is estimated to register significant growth during the forecast period amidst an increasing target patient population, favourable reimbursement scenario, and rising disposable income.

“Moreover, the APAC region has experienced a rise in investments by governments and major players, offering significant growth opportunities for the key players,” the report said.